4D Molecular Therapeutics, Inc. (FDMT) earnings
FDMT earnings moved a median of -0.45% by the close. Quarterly and annual FDMT reports and results, each read against the price at its own news timestamp. Back to the FDMT overview →
21 measured FDMT earnings events.
Where these FDMT earnings landedvs 21 measured FDMT earnings reactions
| Middle 50% of FDMT earnings reactions | -5.23% to +2.02% |
|---|---|
| Median reaction (to close) | -0.45% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 FDMT earnings events with a measured close landed between -5.23% and +2.02%; 43% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones | Press release | -1.80% | +4.82% | |
| Form 10-Q 4D Molecular Therapeutic For: Jun 30 | SEC filing · Form 10-Q | -1.80% | +4.82% | |
| 4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones | Press release | +5.12% | +11.67% | |
| Form 10-Q 4D Molecular Therapeutic For: Mar 31 | SEC filing · Form 10-Q | +5.12% | +11.67% | |
| Form 10-K 4D Molecular Therapeutic For: Dec 31 | SEC filing · Form 10-K | -10.56% | -9.66% | |
| 4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Press release | -0.14% | -1.64% | |
| Form 10-Q 4D Molecular Therapeutic For: Sep 30 | SEC filing · Form 10-Q | -0.14% | -1.64% | |
| 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Press release | -0.89% | -1.60% | |
| Form 10-Q 4D Molecular Therapeutic For: Jun 30 | SEC filing · Form 10-Q | -0.89% | -1.60% | |
| 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Press release | +0.46% | -5.23% | |
| Form 10-Q 4D Molecular Therapeutic For: Mar 31 | SEC filing · Form 10-Q | +0.46% | -5.23% | |
| Form 10-K 4D Molecular Therapeutic For: Dec 31 | SEC filing · Form 10-K | +3.50% | -9.41% | |
| 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones | Press release | -3.18% | +1.91% | |
| Form 10-Q 4D Molecular Therapeutic For: Sep 30 | SEC filing · Form 10-Q | -3.18% | +1.91% | |
| 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights | Press release | -0.54% | -5.61% | |
| Form 10-Q 4D Molecular Therapeutic For: Jun 30 | SEC filing · Form 10-Q | -0.54% | -5.61% | |
| 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights | Press release | +0.69% | +2.02% | |
| Form 10-Q 4D Molecular Therapeutic For: Mar 31 | SEC filing · Form 10-Q | +0.69% | +2.02% | |
| Form 10-K 4D Molecular Therapeutic For: Dec 31 | SEC filing · Form 10-K | -1.58% | +2.09% | |
| 4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights | Press release | +0.49% | -0.45% | |
| Form 10-Q 4D Molecular Therapeutic For: Sep 30 | SEC filing · Form 10-Q | +0.49% | -0.45% |
Keep exploring
More FDMT: analyst actions → · SEC filings → · FDMT overview →